BACKGROUND: During hospitalization for hematopoietic stem cell transplantation (HCT), patients experience a steep deterioration in quality of life (QOL) and mood. To our knowledge, the impact of this deterioration on patients' QOL and posttraumatic stress disorder (PTSD) symptoms after HCT is unknown. METHODS: We conducted a prospective longitudinal study of patients hospitalized for HCT. They assessed QOL using the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) and depression and anxiety symptoms were assessed using the Patient Health Questionnaire-9 (PHQ-9) at the time of admission for HCT, during hospitalization, and 6 months after HCT. We also used the Hospital Anxiety and Depression Scale (HADS) to measure patients' anxiety and depression symptoms at baseline and during HCT hospitalization. The PTSD Checklist was used to assess for PTSD symptoms. Multivariable linear regression models were used to identify predictors of QOL and PTSD symptoms at 6 months. RESULTS: We enrolled 90 of 93 consecutively eligible patients (97%) undergoing autologous and allogeneic HCT. Data at 6 months were available for 67 participants. At 6 months, 28.4% of participants met the criteria for PTSD and 43.3% had clinically significant depression. On multivariable regression analyses adjusting for significant covariates, changes in QOL and depression scores from week 2 of HCT hospitalization to baseline predicted worse QOL (changes in scores between week 2 and baseline [Δ] QOL: β, 0.94 [P<.0001] and Δ PHQ-9: β, -2.59 [P = 0.001]) and PTSD symptoms (Δ QOL: β, -0.40 [P<.0001] and Δ PHQ-9: β, 1.26 [P<.0001]) at 6 months after HCT. CONCLUSIONS: Six months after HCT, a significant percentage of patients met the criteria for PTSD and depression. A decline in QOL and an increase in depressive symptoms during hospitalization for HCT were found to be the most important predictors of 6-month QOL impairment and PTSD symptoms. Therefore, managing symptoms of depression and QOL deterioration during HCT hospitalization may be critical to improving QOL at 6 months and reducing the risk of PTSD. Cancer 2016;122:806-812.
BACKGROUND: During hospitalization for hematopoietic stem cell transplantation (HCT), patients experience a steep deterioration in quality of life (QOL) and mood. To our knowledge, the impact of this deterioration on patients' QOL and posttraumatic stress disorder (PTSD) symptoms after HCT is unknown. METHODS: We conducted a prospective longitudinal study of patients hospitalized for HCT. They assessed QOL using the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) and depression and anxiety symptoms were assessed using the Patient Health Questionnaire-9 (PHQ-9) at the time of admission for HCT, during hospitalization, and 6 months after HCT. We also used the Hospital Anxiety and Depression Scale (HADS) to measure patients' anxiety and depression symptoms at baseline and during HCT hospitalization. The PTSD Checklist was used to assess for PTSD symptoms. Multivariable linear regression models were used to identify predictors of QOL and PTSD symptoms at 6 months. RESULTS: We enrolled 90 of 93 consecutively eligible patients (97%) undergoing autologous and allogeneic HCT. Data at 6 months were available for 67 participants. At 6 months, 28.4% of participants met the criteria for PTSD and 43.3% had clinically significant depression. On multivariable regression analyses adjusting for significant covariates, changes in QOL and depression scores from week 2 of HCT hospitalization to baseline predicted worse QOL (changes in scores between week 2 and baseline [Δ] QOL: β, 0.94 [P<.0001] and Δ PHQ-9: β, -2.59 [P = 0.001]) and PTSD symptoms (Δ QOL: β, -0.40 [P<.0001] and Δ PHQ-9: β, 1.26 [P<.0001]) at 6 months after HCT. CONCLUSIONS: Six months after HCT, a significant percentage of patients met the criteria for PTSD and depression. A decline in QOL and an increase in depressive symptoms during hospitalization for HCT were found to be the most important predictors of 6-month QOL impairment and PTSD symptoms. Therefore, managing symptoms of depression and QOL deterioration during HCT hospitalization may be critical to improving QOL at 6 months and reducing the risk of PTSD. Cancer 2016;122:806-812.
Authors: Stephanie J Lee; Steven Joffe; Haesook T Kim; Gerard Socie; Andrew L Gilman; John R Wingard; Mary M Horowitz; David Cella; Karen L Syrjala Journal: Blood Date: 2004-06-15 Impact factor: 22.113
Authors: S J Lee; D Fairclough; S K Parsons; R J Soiffer; D C Fisher; R L Schlossman; J H Antin; J C Weeks Journal: J Clin Oncol Date: 2001-01-01 Impact factor: 44.544
Authors: Paul B Jacobsen; Ian J Sadler; Margaret Booth-Jones; Elizabeth Soety; Michael A Weitzner; Karen K Fields Journal: J Consult Clin Psychol Date: 2002-02
Authors: M Díez-Campelo; J A Pérez-Simón; J R González-Porras; J M García-Cecilia; M Salinero; M D Caballero; M C Cañizo; E M Ocio; J F San Miguel Journal: Bone Marrow Transplant Date: 2004-10 Impact factor: 5.483
Authors: Karen L Syrjala; Shelby L Langer; Janet R Abrams; Barry Storer; Jean E Sanders; Mary E D Flowers; Paul J Martin Journal: JAMA Date: 2004-05-19 Impact factor: 56.272
Authors: Anna Barata; Brian D Gonzalez; Steven K Sutton; Brent J Small; Paul B Jacobsen; Teresa Field; Hugo Fernandez; Heather Sl Jim Journal: J Health Psychol Date: 2016-04-22
Authors: Jessica Liang; Stephanie J Lee; Barry E Storer; Bronwen E Shaw; Eric J Chow; Mary E Flowers; Elizabeth F Krakow; Merav Bar; Karen L Syrjala; Rachel B Salit; Chareeni E Kurukulasuriya; Heather S L Jim Journal: Biol Blood Marrow Transplant Date: 2018-08-09 Impact factor: 5.742
Authors: Areej El-Jawahri; Thomas LeBlanc; Harry VanDusen; Lara Traeger; Joseph A Greer; William F Pirl; Vicki A Jackson; Jason Telles; Alison Rhodes; Thomas R Spitzer; Steven McAfee; Yi-Bin A Chen; Stephanie S Lee; Jennifer S Temel Journal: JAMA Date: 2016-11-22 Impact factor: 56.272
Authors: Areej El-Jawahri; Sarah R Fishman; Julie Vanderklish; Don S Dizon; Nicole Pensak; Lara Traeger; Joseph A Greer; Elyse R Park; Netana Markovitz; Lauren Waldman; Chrisa Hunnewell; Meredith Saylor; Jessica Driscoll; Zhigang Li; Thomas R Spitzer; Steven McAfee; Yi-Bin Chen; Jennifer S Temel Journal: Cancer Date: 2018-03-14 Impact factor: 6.860
Authors: Margaret Bevans; Areej El-Jawahri; D Kathryn Tierney; Lori Wiener; William A Wood; Flora Hoodin; Erin E Kent; Paul B Jacobsen; Stephanie J Lee; Matthew M Hsieh; Ellen M Denzen; Karen L Syrjala Journal: Biol Blood Marrow Transplant Date: 2016-09-19 Impact factor: 5.742
Authors: Ryan D Nipp; Areej El-Jawahri; Sara M D'Arpino; Andy Chan; Charn-Xin Fuh; P Connor Johnson; Daniel E Lage; Risa L Wong; William F Pirl; Lara Traeger; Barbara J Cashavelly; Vicki A Jackson; David P Ryan; Ephraim P Hochberg; Jennifer S Temel; Joseph A Greer Journal: Cancer Date: 2018-06-15 Impact factor: 6.860
Authors: Areej El-Jawahri; Thomas W LeBlanc; Linda J Burns; Ellen Denzen; Christa Meyer; Lih-Wen Mau; Eric J Roeland; William A Wood; Effie Petersdorf Journal: Cancer Date: 2018-10-05 Impact factor: 6.860